Navigation Links
Common Drug Eases Restless Legs Syndrome
Date:4/29/2009

Lyrica also improves quality of sleep for patients, study finds,,,,

WEDNESDAY, April 29 (HealthDay News) -- Lyrica, a drug used to treat epilepsy, nerve pain, anxiety and fibromyalgia, shows promise in easing the symptoms of restless legs syndrome, a Spanish researcher reports.

Some 5 percent to 10 percent of adults in the United States have restless legs syndrome (RLS), a disorder that causes people to feel a compelling need to move their legs, especially while lying down. The condition can have a substantial impact on sleep, daily activities and quality of life, researchers say.

"This is the first time this drug is being tried for RLS," said Dr. Diego Garcia-Borreguero, director of the Sleep Research Institute in Madrid. "Pregabalin [Lyrica] is an effective drug for the treatment of RLS -- it leads about 60 percent of patients into clinical remission."

The drug improves both the sensation and motor symptoms of RLS, Garcia-Borreguero said.

He also noted that patients taking Lyrica had improved quality of sleep. "Other drugs for RLS had not been able to solve this problem," he said. "They have not been able to improve sleep."

This use of Lyrica is an off-label one, Garcia-Borreguero cautioned.

The findings were to be presented Wednesday at the American Academy of Neurology's annual meeting, in Seattle.

For the study, Garcia-Borreguero randomly assigned 58 people with RLS to Lyrica or a placebo. Sleep studies were performed at the beginning and end of the 12-week trial.

Garcia-Borreguero found that almost 75 percent of patients taking Lyrica had RLS symptoms stop while taking the drug. Among those who continued to have RLS, their symptoms improved by 66 percent. Patients on placebo saw their symptoms worsen by 29 percent.

In addition, those taking Lyrica had better sleep compared with patients taking placebo. Patients on Lyrica had more slow-wave sleep, or deep sleep. They also spent less time in the lighter sleep stages compared with people taking placebo, Garcia-Borreguero said.

RLS presents as an urge to move the legs, often with unpleasant numbness, tingling or burning sensations. These symptoms increase during rest and are partially relieved through activity. Symptoms worsen at night and tend to progress with age.

The study was funded by Pfizer Inc., the maker of Lyrica.

Dr. Carlos Singer, director of the Movement Disorders Center at the University of Miami School of Medicine, thinks Lyrica provides an alternative to other drugs for RLS and may also have fewer side effects.

"You have another weapon to treat RLS," Singer said. "This drug, to the best of my knowledge, has a very safe record," he said. "I would definitely try it with patients."

Singer noted that more studies are needed to see if the drug is still effective for RLS after long-term use.

More information

For more information on restless legs syndrome, visit the U.S. National Institute of Neurological Disorders and Stroke.



SOURCES: Diego Garcia-Borreguero, M.D., director, Sleep Research Institute, Madrid, Spain; Carlos Singer, M.D., professor, neurology, and director, Movement Disorders Center, University of Miami School of Medicine; April 29, 2009, presentation, American Academy of Neurology's annual meeting, Seattle


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Penn Medicine, CHOP researchers demonstrate first common genetic risk factors for autism
2. Mental health problems more common in kids who feel racial discrimination
3. Type of vitamin B1 could treat common cause of blindness
4. Commonly used ulcer drugs may offer treatment potential in Alzheimers disease
5. The Most Common Cause of Hair Loss Is the Least Suspected, Warns Trichology Expert
6. Canadian Medical Device Set to Speed Treatment and Cut Health Care Costs for Common Cause of Vertigo
7. Silent Heart Attacks More Common Than Thought
8. Mayo Clinic-led researchers confirm gene variants associated with the most common adult leukemia
9. All Persons Who Purchased or Acquired the Common Stock of Sunrise Senior Living, Inc. (Sunrise) Between February 26, 2004 and July 28, 2006, Inclusive, and Were Damaged Thereby (The Class)
10. Tianyin Pharmaceutical Co., Inc. Series A Preferred Shareholders Approved Cash Dividend to Common Stockholders
11. Common Industrial Chemicals May Not Boost Cancer Risk
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Common Drug Eases Restless Legs Syndrome
(Date:12/2/2016)... ... December 02, 2016 , ... U.S. Surgeon General, Dr. Vivek ... Dr. Murthy explains how he was inspired to practice medicine at an early age ... is about more than making diagnoses and prescribing medicine,” he states. “It is about ...
(Date:12/2/2016)... ... December 02, 2016 , ... Dr. Raffi Hovsepian, a leading ... the 2016 “Guide to America’s Top Plastic Surgeons” for seven consecutive years. The ... education, experience, and professional associations. , One the most frequently honored surgeons ...
(Date:12/2/2016)... ... December 02, 2016 , ... ... of its SaaS LIMS, CloudLIMS Lite. CloudLIMS Lite helps biobanks, clinical, research and ... storing, shipping and disposal. The new version is a faster and a more ...
(Date:12/2/2016)... (PRWEB) , ... December 02, 2016 , ... Sourced from ... has some unique properties including its unmatched natural purity of just 6 ppm TDS ... and crisp. , Nothing Water has been available in several ShopRite and FoodTown stores ...
(Date:12/2/2016)... ... December 02, 2016 , ... "Pro3rd Accents Volume 2 is ... create versatile lower third titles with just a few clicks of the mouse," said ... includes 30 lower third animations. Choose from various styles with accented animations, rigid boxes, ...
Breaking Medicine News(10 mins):
(Date:12/2/2016)... On Thursday, the NASDAQ Composite ended the trading ... edged 0.36% higher, to finish at 19,191.93; and the S&P ... as six out of nine sectors ended the day in ... Services equities: Myriad Genetics Inc. (NASDAQ: MYGN ), ... Inc. (NASDAQ: INCR ), and La Quinta Holdings ...
(Date:12/2/2016)... to announce that 12 scientific abstracts have been accepted for ... Society (AES) Annual Meeting, which takes place from 2-6 December ... Data being presented include posters further describing ... CV and BRIVIACT ® (brivaracetam) CV. 2,3,4,6,8 Presentations ... union of epilepsy care and antiepileptic drugs in the U.S. ...
(Date:11/30/2016)... DUBLIN , Nov 30, 2016 ... "US Market Overview for Neuromodulation, Neurovascular, Neurosurgical and Monitoring ... ... The full report suite on ... cerebrospinal fluid external drainage systems, intracranial pressure monitoring devices, detachable ...
Breaking Medicine Technology: